Healthcare Industry News: osteoporosis
News Release - July 1, 2011
Medtronic Introduces the CD HORIZON(R) Fenestrated Screw Spinal SystemEurope first in line to receive Medtronic’s innovative product
MEMPHIS, Tenn.--(Healthcare Sales & Marketing Network)-- Medtronic, Inc. (NYSE:MDT ) today announced the European launch of the CD HORIZON® Fenestrated Screw Spinal System, which is used in conjunction with Fenestrated Screw Cement. Starting in Europe, this commercial release will be continued in India, Singapore and Australia in the coming months. This product is not available in the United States.
The CD HORIZON® Fenestrated Screw Spinal System provides surgeons a solution for addressing patients with poor or compromised bone quality as a result of pathologies such as osteoporosis, a condition in which the bone becomes extremely porous, heals slowly and is subject to fracture. This system features a pedicle screw with additional holes in the tip to allow a specially formulated bone cement to be injected into a patient’s vertebral body. This cement then cures and provides enhanced fixation in the patient’s spine.
“This launch continues to demonstrate our commitment to global innovation,” says Doug King, senior vice president and president of Medtronic Spinal. “European surgeons will be the first to use this exciting new technology to provide enhanced treatment options to their patients.”
The CD HORIZON® Fenestrated Screw Spinal System is intended to help provide immobilization and stabilization of spinal segments as an adjunct to fusion of the thoracic, lumbar and/or sacral spine. Potential risks associated with the use of the device include, but are not limited to: disassembly, bending and/or breakage of any or all of the components, and tissue or nerve damage caused by improper positioning and placement of implants or instruments. Severe adverse events associated with the use of acrylic bone cements include cardiac arrest and embolism.
About the Spinal Business at Medtronic
The Spinal business, based in Memphis, Tenn., is the global leader in today’s spine market and is committed to advancing the treatment of spinal conditions. The Spinal business collaborates with world-renowned surgeons, researchers and innovative partners to offer state-of-the-art products and technologies for neurological, orthopaedic and spinal conditions. Medtronic is committed to developing affordable, minimally invasive procedures that provide lifestyle friendly surgical therapies. More information about the company and its spinal treatments can be found at www.medtronicspinal.com and its patient-education Web sites, www.back.com, www.iscoliosis.com, www.maturespine.com and www.necksurgery.com.
Medtronic, Inc. (www.medtronic.com), headquartered in Minneapolis, is the global leader in medical technology – alleviating pain, restoring health and extending life for millions of people around the world.
Any forward-looking statements are subject to risks and uncertainties such as those described in Medtronic’s periodic reports on file with the Securities and Exchange Commission. Actual results may differ materially from anticipated results.
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.